Accuracy Assessment of the GlucoMen® Day CGM System in Individuals with Type 1 Diabetes: A Pilot Study

Biosensors (Basel). 2022 Feb 9;12(2):106. doi: 10.3390/bios12020106.

Abstract

The aim of this study was to evaluate the accuracy and usability of a novel continuous glucose monitoring (CGM) system designed for needle-free insertion and reduced environmental impact. We assessed the sensor performance of two GlucoMen® Day CGM systems worn simultaneously by eight participants with type 1 diabetes. Self-monitoring of blood glucose (SMBG) was performed regularly over 14 days at home. Participants underwent two standardized, 5-h meal challenges at the research center with frequent plasma glucose (PG) measurements using a laboratory reference (YSI) instrument. When comparing CGM to PG, the overall mean absolute relative difference (MARD) was 9.7 [2.6-14.6]%. The overall MARD for CGM vs. SMBG was 13.1 [3.5-18.6]%. The consensus error grid (CEG) analysis showed 98% of both CGM/PG and CGM/SMBG pairs in the clinically acceptable zones A and B. The analysis confirmed that GlucoMen® Day CGM meets the clinical requirements for state-of-the-art CGM. In addition, the needle-free insertion technology is well tolerated by users and reduces medical waste compared to conventional CGM systems.

Keywords: CGM; accuracy; diabetes technology; sustainability; type 1 diabetes.

MeSH terms

  • Blood Glucose / chemistry
  • Blood Glucose / metabolism*
  • Blood Glucose Self-Monitoring* / instrumentation
  • Diabetes Mellitus, Type 1* / blood
  • Humans
  • Pilot Projects
  • Reproducibility of Results
  • Technology

Substances

  • Blood Glucose

Grants and funding